MDT

99.08

-0.7%↓

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

MDT

99.08

-0.7%↓

146.15

-0.93%↓

VEEV

242.59

+1.29%↑

HQY

97.21

-0.08%↓

PHR.US

16.97

-2.64%↓

Home・Akciju saraksts・Certara Inc

Certara Inc

Atvērts

SektorsVeselības aprūpe

9.71 1.78

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.38

Max

9.85

Galvenie mērījumi
By Trading Economics
Ienākumi	3.5M 1.5M
Pārdošana	46K 105M
P/E Sektora vidējais	129.143 87.826
Peļņas marža	1.458
Darbinieki	1,487
EBITDA	-6.5M 23M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+27.61% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-439M 1.4B
Iepriekšējā atvēršanas cena	7.93
Iepriekšējā slēgšanas cena	9.71

Ziņu noskaņojums

By Acuity

50%

166 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

11.27 / 12.79 Atbalsts un pretestība

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. janv. 23:11 UTC

Peļņas

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026. g. 7. janv. 22:55 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026. g. 7. janv. 21:39 UTC

Galvenie tirgus virzītāji

Raytheon Down Following Trump Post Criticizing Company

2026. g. 7. janv. 20:13 UTC

Galvenie tirgus virzītāji

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026. g. 7. janv. 20:03 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026. g. 7. janv. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026. g. 7. janv. 23:34 UTC

Tirgus saruna

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026. g. 7. janv. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026. g. 7. janv. 22:48 UTC

Tirgus saruna

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026. g. 7. janv. 22:46 UTC

Peļņas

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026. g. 7. janv. 22:45 UTC

Peļņas

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026. g. 7. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026. g. 7. janv. 22:42 UTC

Peļņas

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026. g. 7. janv. 22:40 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026. g. 7. janv. 22:31 UTC

Tirgus saruna

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026. g. 7. janv. 22:22 UTC

Tirgus saruna

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026. g. 7. janv. 22:01 UTC

Tirgus saruna

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026. g. 7. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. janv. 21:46 UTC

Tirgus saruna

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026. g. 7. janv. 21:22 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026. g. 7. janv. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026. g. 7. janv. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026. g. 7. janv. 20:29 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Near Deal for Revolution Medicines -- Update

2026. g. 7. janv. 20:27 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026. g. 7. janv. 19:58 UTC

Tirgus saruna

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026. g. 7. janv. 19:48 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

27.61% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD 27.61%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Certara Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Noskaņojums

By Acuity

166 / 372 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.